Search

Displaying results 5621 - 5630 of 7479 in total
  1. Drug

    WVE-003

    go.drugbank.com/drugs/DB17870
    Investigational

    WVE-003 is an allele-selective antisense oligonucleotide that works to selectively reduce the toxic mutant huntingtin (mHTT) protein.[L46787]

  2. Drug

    AVB-001

    go.drugbank.com/drugs/DB18452
    Investigational

    AVB-001 is an encapsulated, engineered human ARPE-19 cell line that constitutively expresses the native human IL-2 cytokine

  3. Drug

    BBT-877

    go.drugbank.com/drugs/DB18668
    Investigational

    BBT-877 is an autotaxin enzyme inhibitor being investigated for the treatment of fibrotic diseases, such as idiopathic pulmonary fibrosis.

  4. Drug

    Capromorelin

    go.drugbank.com/drugs/DB15205
    Investigational

    Capromorelin is under investigation in clinical trial NCT00527046 (Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults).

  5. Drug

    ORE-1001

    go.drugbank.com/drugs/DB12271
    Investigational

    It is an ACE2 inhibitor.

  6. Drug

    Streptolydigin

    go.drugbank.com/drugs/DB04785
    Experimental

    Streptolydigin is an antibiotic isolated from culture filtrates of Streptomyces lydicus. It is active against gram-postive bacteria except micrococci.

  7. Drug

    Erteberel

    go.drugbank.com/drugs/DB07933
    Investigational

    Erteberel is an estrogen receptor beta agonist that has been used in trials studying the treatment of Benign Prostatic Hyperplasia.

  8. Drug

    Butyric Acid

    go.drugbank.com/drugs/DB03568
    Investigational

    A four carbon acid, CH3CH2CH2COOH, with an unpleasant odor that occurs in butter and animal fat as the glycerol ester.

  9. Drug

    Ligandrol

    go.drugbank.com/drugs/DB13934
    Investigational

    Ligandrol is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis.

  10. Drug

    MaaT013

    go.drugbank.com/drugs/DB18648
    Investigational

    MaaT013 is an allogeneic fecal microbiota therapy. It is being investigated for the treatment of Graft-Versus-Host Disease.